Dr. Stacy B. Slechta, DO
Family Medicine (Family Medicine Physician)
700 Medical Center Drive, Suite 210
Newton, KS 67114
Who else practices at this address →
Harvey County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Kansas City University of Med & Biosciences, College of Osteo Med (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 383
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Kansas City University of Med & Biosciences, College of Osteo Med
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
KS license 0528840
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Nmc Health Newton, KS
Medical groups
- Axtell Clinic PA (11 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 383
- Services billed
- 2,264
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 475 | 238 |
| Established patient office or other outpatient visit, 20-29 minutes | 272 | 175 |
| Anticoagulant management of patient taking warfarin | 193 | 13 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 173 | 173 |
| Annual depression screening, 5 to 15 minutes | 143 | 143 |
| Administration of influenza virus vaccine | 40 | 40 |
| Influenza vaccine split virus, preservative free | 38 | 38 |
| Administration of pneumococcal vaccine | 33 | 33 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 31 | 31 |
| Urinalysis, manual test | 29 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 73 payments worth $1,282 in total to this clinician.
| AbbVie Inc. | $308 |
|---|---|
| Pfizer Inc. | $243 |
| AstraZeneca Pharmaceuticals LP | $227 |
| Bayer HealthCare Pharmaceuticals Inc. | $138 |
| Amgen Inc. | $92.34 |
| Otsuka America Pharmaceutical, Inc. | $88.03 |
| Novo Nordisk Inc | $45.58 |
| Astellas Pharma US Inc | $45.29 |
| Food and Beverage | $1,282 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $681,895 in research payments for these studies, mostly to the institutions running them.
- A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Sanofi Pasteur Inc. · Completed · NCT06744205 - A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight…
AstraZeneca UK Limited - Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.
Sanofi Pasteur Inc. · Completed · NCT05513053 - A master phase 123 protocol to investigate the safety tolerability and immunogenicity of bivalent BNT162B2 rna based vaccine candidates in healthy children
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.